Cong Vu Thanh
Research Subjects
Cong Vu Thanh has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- J. Justin Gooding
University of New South Wales
2 shared publications - Jacinta L. Houng
School of Chemistry, University of New South Wales, Sydney, NSW 2052, Australia
1 shared publication - Maria Kavallaris
Children's Cancer Institute, Lowy Cancer Research Centre, UNSW Sydney, Sydney, NSW, 2052, Australia.
1 shared publication - Melanie Kah
The University of Auckland
1 shared publication - Richard David Tilley
School of Chemistry, University of New South Wales, Sydney, NSW 2052, Australia
1 shared publication - Xin Chen
School of Chemical Engineering and Technology, Shaanxi Key Laboratory of Energy Chemical Process Intensification, Institute of Polymer Science in Chemical Engineering, Xi'an Jiaotong University, Xi'an, 710049, China
1 shared publication
Latest Publications
- Open Access
- 7 March 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-9
Learning lessons from nano-medicine to improve the design and performances of nano-agrochemicals
Sharing concepts and knowledge between medical and agricultural fields can promote the development of improved nano-enabled technologies. A central idea behind drug delivery systems is that the active substances are encapsulated in nanoparticles (nano-medicines) to protect the drugs from premature degradation and allow them to be transported to the target site within the body. After three decades of development, nano-medicines are now used in many practical applications, including clinical oncology, infectious disease, cosmetics, and vaccines. Nano-agrochemicals are increasingly considered to tackle challenges associated with food production, sustainability and food security. Despite obvious differences between nano-medicines and nano-agrochemicals in terms of uptake mechanisms, target and environmental and economic constraints, the principles behind nanoparticle design share many similarities. This article hopes to share experiences and lessons learnt from nano-medicines that will help design more effective and safer nano-agrochemicals.
- 7 March 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-9
Open AccessLearning lessons from nano-medicine to improve the design and performances of nano-agrochemicals
Sharing concepts and knowledge between medical and agricultural fields can promote the development of improved nano-enabled technologies. A central idea behind drug delivery systems is that the active substances are encapsulated in nanoparticles (nano-medicines) to protect the drugs from premature degradation and allow them to be transported to the target site within the body. After three decades of development, nano-medicines are now used in many practical applications, including clinical oncology, infectious disease, cosmetics, and vaccines. Nano-agrochemicals are increasingly considered to tackle challenges associated with food production, sustainability and food security. Despite obvious differences between nano-medicines and nano-agrochemicals in terms of uptake mechanisms, target and environmental and economic constraints, the principles behind nanoparticle design share many similarities. This article hopes to share experiences and lessons learnt from nano-medicines that will help design more effective and safer nano-agrochemicals.
- 8 August 2022
- Published by Royal Society of Chemistry (RSC) in Chemical Society Reviews
- Vol. 51 (17) , 7531-7559
How can we use the endocytosis pathways to design nanoparticle drug-delivery vehicles to target cancer cells over healthy cells?
Targeted drug delivery in cancer typically focuses on maximising the endocytosis of drugs into the diseased cells. However, there has been less focus on exploiting the differences in the endocytosis pathways of cancer cells versus non-cancer cells. An understanding of the endocytosis pathways in both cancer and non-cancer cells allows for the design of nanoparticles to deliver drugs to cancer cells whilst restricting healthy cells from taking up anticancer drugs, thus efficiently killing the cancer cells. Herein we compare the differences in the endocytosis pathways of cancer and healthy cells. Second, we highlight the importance of the physicochemical properties of nanoparticles (size, shape, stiffness, and surface chemistry) on cellular uptake and how they can be adjusted to selectively target the dominated endocytosis pathway of cancer cells over healthy cells and to deliver anticancer drug to the target cells. The review generates new thought in the design of cancer-selective nanoparticles based on the endocytosis pathways.
- 8 August 2022
- Published by Royal Society of Chemistry (RSC) in Chemical Society Reviews
- Vol. 51 (17) , 7531-7559
How can we use the endocytosis pathways to design nanoparticle drug-delivery vehicles to target cancer cells over healthy cells?
Targeted drug delivery in cancer typically focuses on maximising the endocytosis of drugs into the diseased cells. However, there has been less focus on exploiting the differences in the endocytosis pathways of cancer cells versus non-cancer cells. An understanding of the endocytosis pathways in both cancer and non-cancer cells allows for the design of nanoparticles to deliver drugs to cancer cells whilst restricting healthy cells from taking up anticancer drugs, thus efficiently killing the cancer cells. Herein we compare the differences in the endocytosis pathways of cancer and healthy cells. Second, we highlight the importance of the physicochemical properties of nanoparticles (size, shape, stiffness, and surface chemistry) on cellular uptake and how they can be adjusted to selectively target the dominated endocytosis pathway of cancer cells over healthy cells and to deliver anticancer drug to the target cells. The review generates new thought in the design of cancer-selective nanoparticles based on the endocytosis pathways.